Last reviewed · How we verify
non-atorvastatin group
At a glance
| Generic name | non-atorvastatin group |
|---|---|
| Sponsor | xieruiqin |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper Respiratory Tract Infection
- Accidental Overdose
- Nasopharyngitis
- Back pain
- Injection site reaction
Key clinical trials
- Statins Against Bushfire Smoke (PHASE4)
- Combined Effects of Statins and Exercise on Training Sensitive Health Markers (NA)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Statins for the Treatment of NASH (PHASE2)
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (PHASE3)
- Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial (NA)
- Measuring Oncological Value of Exercise and Statin (PHASE3)
- Atorvastatin Effect on Reduction of COPD Exacerbations (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- non-atorvastatin group CI brief — competitive landscape report
- non-atorvastatin group updates RSS · CI watch RSS
- xieruiqin portfolio CI